脐带间充质干细胞替代供者骨髓细胞在单倍体相合造血干细胞移植中的作用  

Efficacy of umbilical cord mesenchymal stem cells replacing donor bone marrow cells in haploidentical hematopoietic stem cell transplantation

作　　者：张文荟 裴晓杭 孔黛 刘忠文 Zhang Wenhui;Pei Xiaohang;Kong Dai;Liu Zhongwen(Department of Hematology,Henan Provincial People’s Hospital,People’s Hospital of Zhengzhou University,Zhengzhou 450002,Henan Province,China)

机构地区：[1]河南省人民医院血液内科,郑州大学人民医院,河南省郑州市450002

出　　处：《中国组织工程研究》2024年第13期2042-2046,共5页Chinese Journal of Tissue Engineering Research

基　　金：河南省医学科技攻关计划省部共建重点项目(SBGJ202102041),项目负责人:刘忠文~。

摘　　要：背景:HLA单倍体相合异基因造血干细胞移植为高危恶性血液病患者提供了生存的机会。近年来,对单倍体相合移植的移植模式及移植物选择的探究仍在进行。目前国内逐渐流行以北京大学血液病研究中心建立的非体外去除T细胞骨髓和外周血干细胞混合移植模式,但此模式需采集供者骨髓液而增加了供者的痛苦和风险。目的:探讨脐带间充质干细胞替代供者骨髓细胞联合单倍体相合外周血造血干细胞移植治疗恶性血液病的疗效。方法:入组2019年1月至2022年5月接受单倍体相合造血干细胞移植的恶性血液病患者50例,按2∶3比例随机分配到2个研究组,其中脐带间充质干细胞+外周血干细胞移植的受者19例,骨髓细胞+外周血干细胞移植的受者31例。该研究经河南省人民医院伦理委员会审批。脐带间充质干细胞的受者于移植当天,首先输注1份第三方脐带间充质干细胞(1×106/kg),6 h后输注外周血造血干细胞。骨髓细胞的受者于移植+1 d输注供者骨髓细胞,于+2 d输注外周血干细胞。移植后所有受者均采用兔抗人胸腺细胞免疫球蛋白+环孢素A+吗替麦考酚酯+短疗程甲氨喋呤预防移植物抗宿主病。结果与结论:脐带间充质干细胞回输无不良事件发生,脐带间充质干细胞组和骨髓组的植入成功率分别为100%(19/19)和96.8%(30/31),差异无显著性意义(P>0.05);两组的粒系植入中位时间分别为14 d和15 d,差异无显著性意义(P>0.05);两组的血小板植入中位时间分别为20 d和19 d,差异无显著性意义(P>0.05);两组Ⅱ-Ⅳ度急性移植物抗宿主病发生率分别为21.1%(4/19)和58.1%(18/31),差异有显著性意义(P=0.01);两组慢性移植物抗宿主病发生率分别为21.1%(4/19)和25.8%(8/31),差异无显著性意义(P>0.05)。两组复发率分别为15.8%(3/19)和16.1%(5/31),差异无显著性意义(P>0.05)。两组早期巨细胞病毒血症发生率分别为42.1%(8/19)和35.5%(11/3BACKGROUND:HLA haploid allogeneic hematopoietic stem cell transplantation provides a chance of survival for patients with high-risk hematologic malignancies.In recent years,the research on the transplantation mode and graft selection of haploidentical transplantation is still ongoing.At present,the mixed transplantation model of non-extracorporeal T-cell removal bone marrow and peripheral blood stem cells established by the Hematology Research Center of Peking University is gradually becoming popular in China,but this model requires the collection of donor bone marrow fluid,which increases the pain and risk of the donor.OBJECTIVE:To explore the curative effect of infusion of umbilical cord mesenchymal stem cells replacing donor bone marrow cells in haploidentical peripheral blood hematopoietic stem cell transplantation for malignant hematological diseases.METHODS:Fifty hematological malignancies patients who underwent haploidentical hematopoietic stem cell transplantation from January 2019 to May 2022 were selected and randomly assigned to two study groups at a ratio of 2:3.Among them,19 patients received umbilical cord mesenchymal stem cell combined with peripheral blood stem cell transplantation,and 31 patients were treated with bone marrow cells combined with peripheral blood stem cells.The study was approved by the Ethics Committee of Henan Provincial People’s Hospital.The recipients of umbilical cord mesenchymal stem cells were first transfused with third-party umbilical cord mesenchymal stem cells(1×106/kg)on the day of transplantation,followed by peripheral blood hematopoietic stem cells 6 hours later.In the bone marrow group,donor bone marrow cells were transfused+1 day after transplantation and peripheral blood stem cells were transfused+2 days after transplantation.After transplantation,rabbit anti-human thymocyte immunoglobulin,cyclosporine A,mycophenolate mofetil,and a short-course methotrexate were used for graft-versus-host disease prophylaxis for all recipients.RESULTS AND CONCLUSION:No adverse

关 键 词：脐带间充质干细胞 单倍体相合造血干细胞移植 急性移植物抗宿主病 恶性血液病 安全性 

分 类 号：R459.9[医药卫生—治疗学] R394.2[医药卫生—临床医学] R551